IMMIX BIOPHARMA, INC. — Income Charts

1 quarters of history · ending 2022-12-08 · SEC EDGAR

Income Statement Cash Flow Balance Sheet Key Metrics

Source:10-K · 10-Q

Revenue, Gross Profit, Operating Income & Net Income

Revenue

$20M

R&D

—

D&A

—

Operating Income

—

EBITDA

—

Interest Expense

—

Interest Income

—

Other Income/Expense

—

Pretax Income

—

Tax Provision

—

Net Income

—

Effective Tax Rate

—

Operating Lease Cost

—

Income YoY Variation

—

Income QoQ Variation

—

No segment data available for this ticker. Source: quarterchart.com.